In case of larger nanobody drug formats, opsonization and subsequent recognition and uptake by the reticuloendothelial system (RES) may occur, leading to hepatic clearance of these therapeutic ...

To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...

The new drug candidate for FSHD will combine an RNA molecule from miRecule targeting double homeobox 4 (DUX4) – a protein that is mutated in FSHD – with a nanobody developed by Sanofi that ...

Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...

Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by ...

is developing drug-conjugated vectors that bind to BBB receptors with high-affinity, triggering transport into and across cells (Fig. 1). “We are developing peptide and nanobody vectors that ...

Nanobodies, also known as single-domain antibodies (sdAbs) or VHH antibodies, are only 1/10th the size of traditional monoclonal antibodies but can retain full antigen-binding potential, establishing ...